Tranzyme Pharma has launched a Phase IIb clinical trial of its proposed treatment for severe gastroparesis, a digestive disorder linked to diabetes.
Tranzyme’s compound TZP-101 is the first in a class of potential treatments for gastrointestinal disorders. It also has a compound in Phase IIb trials for post-operative ileus, or blockages.
The TZP-101 trial is being tested in the U.S., Denmark and Sweden and is designed to test its efficacy. The drug received fast-track status from the U.S. Food and Drug Administration in July.
“As of today, no efficient treatment for diabetic gastroparesis exists,” said Niels Ejskjaer, the principal investigator for the trial. He is a doctor at Aarhus University Hospital in Denmark.
